We are redefining the standard of care for people living with PNH and aHUS with ULTOMIRIS, which has a unique value proposition that is supported by patient preference of going to the hospital every two months, for adults, instead of every
two weeks. In 2020, we will continue leading with ULTOMIRIS as the market leader for PNH and aspire to the same outcome for people living with aHUS.
Living with PNH
Living with aHUS
4x Expansion of U.S. Neurology Treated Patient Population
We continue our efforts to expand our C5 franchise into new areas, where there is great unmet need and opportunity to help even more patients and families.
1. Commercial estimate. 2. Prevalence of ALS-United States, 2015 MMWR Morb Mortal Wkly Rep. 2018 Nov 23; 67(46): 1285-1289. 3. Aligned with our Phase 3 PREVENT criteria. 4. Zimmerhackl, L.B., N. Besbas, T. Jungraithmayr, N. van de Kar, H. Karch, D. Karpman, D. Landau, C. Loirat, W. Proesmans, F. Prufer, G. Rizzoni and M. C. Taylor (2006). “Epidemiology, clinical presentation, and pathophysiology of atypical
and recurrent hemolytic uremic syndrome.” Semin Thromb Hemost 32(2): 113–120. 5. Rosenthal, J., HCT-TMA: a review of pathophysiology, diagnosis, and treatment, 201.
6. Poujois, A., et al. Characteristics and prevalence of Wilson’s disease: A 2013 observational population based study in France. Clin Res Hepatol Gastroenterol. 2018 Feb;42(1):57-6. 7. Risitano AM, et al. Blood. 2009;113(17):4094-4100 8. Quock, T. P., et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018; 2(10):1046-1053 9. Eidos Therapeutics